• Home
  • Sunitinib 12.5mg
  • Sunitinib 12.5mg

Sunitinib 12.5mg

52084

Sunitinib is used for gastrointestinal stromal tumour that has spread or cannot be removed by surgery after imatinib has stopped working or is not tolerated.

It is used for advanced renal cell carcinoma and, in some cases, after kidney surgery to lower the chance of high-risk renal cell carcinoma coming back.

It is also used for pancreatic neuroendocrine tumours that are advanced, well differentiated, and cannot be removed by surgery or have spread.

Usual adult dose range: 25mg to 50mg once daily, either continuously or on a 4-weeks-on, 2-weeks-off schedule depending on the cancer type.

Indications vary by country and change over time; this website contains information for general patient information and should be checked against local prescribing information before clinical use.

Verification Approach: Each indication and usual dose-range sentence was drafted from at least two recognised medicines information sources, usually FDA/DailyMed or an FDA label plus EMA/eMC, MedlinePlus, Mayo Clinic, Cancer Research UK, NCI/ Cancer.gov, or another reputable medicines-information source. Doses are general adult/patient-information ranges and must not be used to prescribe or change treatment.
  • FDA/DailyMed prescribing information and FDA Oncology/Hematology approval notifications.
  • EMA and UK eMC Summary of Product
    Characteristics and patient leaflets where available.
  • NCI Cancer Drug Information/Cancer.gov and Cancer Research UK medicine information where available.
  • MedlinePlus, NHS/NICE, and other national medicines information for non-oncology or immune/respiratory medicines.
  • Peer-reviewed FDA approval summaries or manufacturer regulatory notices for very new, withdrawn, or region-specific
    indications.